

Prof. Dr. Danilo Fliser

Professor of Medicine, Saarland University, Director Department of Internal Medicine IV Renal and Hypertensive Disease & Transplant Centre, Saarland University Medical Centre

Academic Appointments

1990 - 1998	Research Fellow at the Division of Nephrology, Department of Internal Medicine, Ruperto-Carola University, Heidelberg (Germany)
1996	Research Fellow at the Department of Endocrinology and Metabolism, University of Virginia, Charlottesville (USA)
1997	Faculty Rank in Internal Medicine
1998 - 1999	Assistant Professor (Internal Medicine) at the Ruperto-Carola University, Heidelberg (Germany)
1999 - 2007	Associate Professor (Internal Medicine) at the Hannover Medical School, Hannover (Germany) Head of the Clinical Research Unit
2007 -	Professor of Medicine at the Saarland University Director of the Department of Internal Medicine IV - Renal and Hypertensive Disease & Transplant Centre Saarland University Medical Centre Homburg/Saar (Germany)
2016	Chair of the Scientific Committee of the 53 rd ERA-EDTA annual congress in Vienna
2016 - 2018	ERA-EDTA Ordinary Council Member
2017 - 2019	Chair of the Paper Selection Committee for the ERA-EDTA annual congress
2018 – 2021	ERA-EDTA Renal Science Chair & Chairperson of the Administrative Offices

Awards and Honors

1995	<i>Nils Alwall Prize</i>
2004	<i>Bernd Tersteegen Prize</i>
2005	<i>Franz Volhard Prize</i>
2015	<i>FERA</i>

Membership

National

German Society for Internal Medicine
German Hypertension Society
German Society for Nephrology

International

ASN	American Society of Nephrology
EDTA	European Dialysis and Transplant Association
EUTox	European Study Group on Uremia Toxicity
ISN	International Society of Nephrology

Member of the „Editorial Board”

Der Nephrologe (***Managing Editor***)
Journal of the American Society of Nephrology
Kidney International
Nephrology, Dialysis and Transplantation (***Theme Editor***)

Publications

- Original publications listed in PubMed **>340**
- Original publications **>100 times cited** **69**
- **Hirsch Index** (Google) **78**

Original (research) publications with an impact factor >15

Zewinger et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.

Nat Immunol 2020, 21: 30-41

Schunk SJ, et al. Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study.

Lancet 2019; 394: 488-496

Zewinger S, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

Lancet Diabetes Endocrinol 2017; 5: 534-543

Zewinger S, et al. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.

Eur Heart J 2017; 38: 1597-1607

Bauer L, et al. HDL-cholesterol efflux capacity and cardiovascular events in patients with chronic kidney disease.

J Am Coll Cardiol 2017; 69: 246-247

Zewinger S, et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk.

Eur Heart J 2015; 36: 3007-3016

Speer T, et al. Carbamylated low-density lipoprotein induces endothelial dysfunction.

Eur Heart J 2014; 35: 3021-3032

Speer T, et al. Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-Like Receptor-2.

Immunity 2013; 38: 754-768

Rogacev KS, et al. CD14⁺⁺CD16⁺ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography.

J Am Coll Cardiol 2012; 60: 1512-1520

Seiler S, et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.

Eur Heart J 2011; 32: 2688-2696

Rogacev KS, et al. CD14⁺⁺16⁺ monocytes are independent predictors of cardiovascular outcome in patients with chronic kidney disease.

Eur Heart J 2011; 32: 84-92

Zawada AM, et al. SuperSAGE evidence for CD14⁺⁺CD16⁺ monocytes as a third monocyte subset.

Blood 2011; 118: e50-61

Rogacev KS, et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis.

Eur Heart J 2010; 31: 369-376

Sorrentino SA, et al. Oxidant stress impairs in vivo re-endothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: Restoration by peroxisome proliferator-activator receptor-gamma agonist rosiglitazone.

Circulation 2007; 116: 163-173

Landmesser U, et al. Simvastatin vs. Ezetimibe: Pleiotropic vs. lipid lowering effects on endothelial function and endothelial progenitor cells in humans.

Circulation 2005; 111: 2356-2363

Fliser D, et al; for the EUTOPIA investigators (European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis). Anti-inflammatory effects of angiotensin II subtype 1-receptor blockade in hypertensive patients with micro-inflammation.

Circulation 2004; 110: 1103-1107

Bahlmann FH, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.

Circulation 2004; 110: 1006-1012

Kielstein JT, et al. Cardiovascular effects of systemic NO synthase inhibition with asymmetric dimethylarginine in humans.

Circulation 2004; 109: 172-177

Kielstein JT, et al. Asymmetric dimethylarginine (ADMA), renal perfusion and blood pressure in elderly subjects.

Circulation 2003; 107: 1891-1895

Bahlmann FH, et al. Erythropoietin regulates endothelial progenitor cells.

Blood 2003; 103: 921-926